2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission

Mesoblast has established another pillar of the evidence it thinks will support a second run at the FDA for its cell therapy, touting long-term data from the study at the center of its rejected application as the key to its planned resubmission.